



上海醫藥集團股份有限公司

Shanghai Pharmaceuticals Holding Co., Ltd.*

(A joint stock company incorporated in the People's Republic of China with limited liability)

(於中華人民共和國註冊成立的股份有限公司)

(Stock Code 股份代碼：02607)

NOTIFICATION LETTER 通知信函

1 March 2024

Dear Non-Registered Shareholder,

Shanghai Pharmaceuticals Holding Co., Ltd.* (the "Company")

- Notice of Publication of Circular and Notice of Extraordinary General Meeting ("Current Corporate Communication")

The English and Chinese versions of the Current Corporate Communication are available on, and may be accessed under "Announcements & Circulars" in the Investor Relations section of the Company's website at www.sphchina.com and are also available on the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk.

Pursuant to Rule 2.07 of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules"), the Company is required to disseminate corporate communications ("Corporate Communications") electronically. You may access the English and Chinese versions of the Company's Corporate Communications on the Company's website at www.sphchina.com and the HKEXNews website at www.hkexnews.hk.

If you wish to receive notifications from the Company on the availability of Corporate Communications on the Company's website in the future, you may provide a valid email address through your intermediary to HKSCC Nominees Limited. The Company will send a notification to the provided email address each time when Corporate Communications are made available on the Company's website. It is the responsibility of the shareholder to provide an email address that is functional. If the Company does not receive a functional email address from you, you will be unable to receive any notification regarding the publication of Corporate Communications.

We encourage you to access Corporate Communications of the Company in electronic form on the Company's website. If you wish to receive printed copies of Corporate Communications, you may refer to the relevant procedures stated on the Company's website at www.sphchina.com. The Company will promptly upon your request send the requested Corporate Communications to you free of charge.

Should you have any queries relating to any of the above matters, please call the telephone hotline of the Company's H Share Registrar, Link Market Services (Hong Kong) Pty Limited, at (852) 3707 2600 during business hours from 9:00 a.m. to 6:00 p.m. Monday to Friday, excluding public holidays or send an email to hkenquiries@linkmarketservices.com.

By order of the Board
Shanghai Pharmaceuticals Holding Co., Ltd.*
ZHONG Tao
Joint Company Secretary

* For identification purpose only

Corporate communications are all documents issued by the Company to holders of its securities for their information or action and include (but are not limited to) full and summary annual and interim financial reports (and all reports and accounts contained in them), notices of meetings, listing documents, circulars, proxy forms and reply slips.

各位非登記股東：

上海醫藥集團股份有限公司（「公司」）

- 臨時股東大會之通函、通告、代表委任表格及回條（「本次公司通訊」）之發佈通知

本次公司通訊之中、英文版本已上載於公司網站（www.sphchina.com）之投資者關係內的「公告與通函」網頁及香港聯合交易所有限公司披露易網站（www.hkexnews.hk），歡迎查閱。

根據香港聯合交易所有限公司證券上市規則（「上市規則」）第 2.07 條，本公司將須透過電子方式發送公司通訊（「公司通訊」）。閣下可於本公司網站 www.sphchina.com 及香港交易所披露易網站 www.hkexnews.hk 瀏覽本公司的中、英文版本公司通訊。

如閣下日後希望收到本公司的公司通訊已上載於本公司網站的通知，可以透過閣下的中介機構向香港中央結算（代理人）有限公司提供閣下的有效電郵地址。每次本公司於本公司網站上載公司通訊時，本公司將發送通知至閣下提供的電郵地址。股東有責任提供有效的電郵地址。如本公司沒有收到閣下的有效電郵地址，閣下將無法收到任何有關發佈公司通訊的通知。

我們鼓勵閣下於本公司網站以電子形式瀏覽本公司的公司通訊。如閣下希望收取本公司的公司通訊印刷本，可以參考本公司網站 www.sphchina.com 註明的相關程序。本公司將盡快免費向閣下寄上所需要的公司通訊的印刷本。

如閣下對本函內容有任何疑問，請致電本公司H股證券登記處 Link Market Services (Hong Kong) Pty Limited 的電話熱線(852) 3707 2600，辦公時間為星期一至五（公眾假期除外）上午9時正至下午6時正，或電郵至 hkenquiries@linkmarketservices.com。

承董事會命
上海醫藥集團股份有限公司
聯席公司秘書
鐘濤

二零二四年三月一日

* 僅供識別

公司通訊乃公司向其證券持有人發出以供參照或採取行動的任何文件，包括但不限於年度和中期財務報告及其摘要報告（及其中包含的所有報告及帳目）、會議通告、上市文件、通函、代表委任表格及回條。